<DOC>
	<DOCNO>NCT03101514</DOCNO>
	<brief_summary>About 89 % -100 % patient head neck malignant tumor radiation mucositis radiotherapy . Until , effective method prevent mucositis . Steroid hormone , pain-relief , anti-inflammatory symptom-relief treatment usually use emergence mucositis . Coixenol triglyceride ester extract Coix Seed . Its trade name Kanglaite Injection , approve China Russia . Kanglaite anti-tumor effect reduce treatment toxicity tumor . Kanglaite could also improve quality life patient mitigate condition cachexia . In china , two study evaluate treatment Kanglaite nasopharyngeal cancer , find Kanglaite reduce radiotherapy mucositis . So far , Kanglaite prevention treatment radiation mucositis head neck malignant tumor still lack strong clinical trial evidence . This phase II , single center , one arm study subject evaluate acute radiation mucositis , nutritional status , quality life course radiotherapy head neck cancer .</brief_summary>
	<brief_title>Kanglaite Reduce Toxicity Radiotherapy Head Neck Cancer Phase II Study</brief_title>
	<detailed_description>3-4 grade radiation mucositis account 34 % -56 % head neck patient treat radiotherapy &gt; 50 % patient treat radiotherapy concurrent chemotherapy . 3-4 grade radiation mucositis obvious symptom , present fusion ulcer , ulcer bleed obvious pain need analgesic drug . At time , patient eat intake fluid diet , lead weight loss , malnutrition , quality life decline series problem . Kanglaite anti-tumor effect reduce treatment toxicity tumor . Kanglaite reduce radiotherapy mucositis nasopharyngeal cancer find initially Chinese . Kanglaite prevention treatment radiation mucositis head neck malignant tumor still lack strong clinical trial evidence . This phase II , single center , one arm study subject evaluation acute radiation mucositis , nutritional status , quality life course radiotherapy head neck malignant tumor . Kanglaite 200ml inject intravenous first day last day radiotherapy . Chemotherapy cisplatin nedaplatin ( 80-100mg/m2 , 21 day per cycle , 1-3 cycle ) use concurrent radiotherapy . There order Kanglaite injection radiotherapy . Granulocyte colony stimulate factor antibiotic prophylactic use , use decline white blood cell . Mucositis , nutritional status , quality life evaluate radiotherapy , every week radiotherapy , 4 week radiotherapy . Mucositis verify physical examination . Nutritional status evaluate patient-generated subjective global assessment ( PG-SGA ) scale . Quality life evaluate EORTC QLQ-C30 QLQ-H &amp; N35 questionnaire . This one arm study , sample size calculation base incidence 3-4 degree mucositis . The incidence 3-4 degree mucositis &gt; 50 % accord literature head neck squamous cell carcinoma intensity modulate radiation therapy concurrent chemotherapy . So assume Kanglaite reduce 3-4 degree mucositis 50 % 30 % . The sample size require 44 case accord superiority test , bilateral Class I error α = 0.05 , class II error β = 0.2 . Total 49 case need , assume rate 10 % .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>1 . 1880 year old , expect survival period ≥ 12 month 2 . Karnofsky score ≥80 point 3 . Pathological confirm head neck malignant tumor ( oral , oropharynx , hypopharynx , throat , nasopharynx , nasal paranasal sinus ) , radical radiotherapy ( ± chemotherapy ) postoperative radiotherapy ( ± chemotherapy ) , radiotherapy dose 60 70Gy 4. without induction chemotherapy ( induced chemotherapy ≤ 3 cycle ) ; 5 . Meet follow laboratory diagnostic indicator : Hemoglobin ≥120g / L , white blood cell 4.010.0 × 109 / L , neutrophils 2.07.5 × 109 / L , platelets 100300 × 109 / L ; creatinine ≤ normal upper limit ( UNL ) ; ALT AST ≤ 2.5 × UNL , alkaline phosphatase ( ALP ) ≤ 5 × UNL , total bilirubin ( Tbil ) ≤ UNL 6 . Sign inform consent . 1 . Distant metastases 2 . Allergy Kanglaite 3 . Head neck previously receive radiation therapy 4 . Pregnancy lactation patient 5 . Targeted drug therapy radiotherapy 6 . Radiochemotherapy use cytotoxic drug platinum 7 . Currently active infection , combine rheumatic immune disease , longterm chronic infection , acute infection , inflammatory state ; hematopoietic dysfunction blood system diseases ; severe cardiopulmonary disease 8 . Mental history , cooperate treatment 9 . Researchers believe unsuitable participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>head neck</keyword>
	<keyword>tumor</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>mucositis</keyword>
	<keyword>toxicity</keyword>
	<keyword>Kanglaite injection</keyword>
</DOC>